depemokimab
Trade name: Exendsur
mAbapproved
Approved
Dec 16, 2025
Clinical trial activity
15 trials · 3 clinical orgs · 1 marketing orgs
Phase 1
3
Phase 2
12
Phase 3
12
Phase 4
0
Earliest trial started Oct 17, 2017 (NCT03287310)
Timeline
2010s
- Jan 1, 2017
GlaxoSmithKline — Earliest Phase 1 Sponsor(trial)
2020s
- Jan 1, 2021
GlaxoSmithKline — Earliest Phase 3 Sponsor(trial)
- Dec 16, 2025
Earliest FDA Approval
- Dec 16, 2025
GlaxoSmithKline — Marketing Organization
Indications
Approved for
Mechanism of action
- Interleukin-5INHIBITOR
Interleukin-5 inhibitor
Approval history
- approvedDec 16, 2025
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4650469 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07177339 | Phase 3 | Oct 20, 2025 | GlaxoSmithKline |
| NCT06961214 | Phase 3 | Jun 23, 2025 | GlaxoSmithKline |
| NCT06959095 | Phase 3 | Jun 20, 2025 | GlaxoSmithKline |
| NCT06979323 | Phase 3 | Jun 3, 2025 | GlaxoSmithKline |
| NCT05602025 | Phase 1 | Dec 16, 2022 | GlaxoSmithKline, PPD |
| NCT05334368 | Phase 3 | Sep 6, 2022 | GlaxoSmithKline |
| NCT05263934 | Phase 3 | Jul 14, 2022 | GlaxoSmithKline |
| NCT05274750 | Phase 3 | Apr 22, 2022 | GlaxoSmithKline |
| NCT05281523 | Phase 3 | Apr 18, 2022 | GlaxoSmithKline |
| NCT05243680 | Phase 3 | Mar 1, 2022 | GlaxoSmithKline, IQVIA |
| NCT05140200 | Phase 1 | Dec 1, 2021 | GlaxoSmithKline |
| NCT04719832 | Phase 3 | Mar 17, 2021 | GlaxoSmithKline, IQVIA |
| NCT04718103 | Phase 3 | Feb 25, 2021 | GlaxoSmithKline, IQVIA |
| NCT04718389 | Phase 3 | Jan 26, 2021 | GlaxoSmithKline, IQVIA |
| NCT03287310 | Phase 1 | Oct 17, 2017 | GlaxoSmithKline |
Showing 15 of 15 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| GlaxoSmithKline | For profit | 15 | 15 | 2 | 2017 |
| IQVIA | For profit | 4 | 0 | 1 | 2021 |
| PPD | For profit | 1 | 0 | 1 | 2022 |
3 organizations
Page 1 / 1
Marketing (1)
| Organization | Org type | Relationship | Date |
|---|---|---|---|
| GlaxoSmithKline | For profit | MKTG | Dec 16, 2025 |